Jade Biosciences, Inc. Convertible Notes Payable, Noncurrent
Jade Biosciences, Inc. (JBIO) had Convertible Notes Payable, Noncurrent of $0 as of 2025-12-31, per its 10-K filed 2026-03-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:ConvertibleLongTermNotesPayable · last filed 2026-03-06
- 2025-12-31: Convertible Notes Payable, Noncurrent $0.00.
- 2025-09-30: Convertible Notes Payable, Noncurrent $0.00.
- 2024-12-31: Convertible Notes Payable, Noncurrent $107.60M.
- 2024-06-17: Convertible Notes Payable, Noncurrent $129.20M.
| Period end | Convertible Notes Payable, Noncurrent |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-06 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 |
| 2024-12-31 | $107.60M 10-K · filed 2026-03-06 |
| 2024-06-17 | $129.20M 10-K · filed 2026-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |